A gene therapy that has allowed several children born deaf to hear for the first time is being hailed as a “game changer” that raises hopes of the first new treatment for hereditary deafness in decades.
Several medical teams around the world are trialling the procedure, which focuses on a rare genetic mutation that affects only a small number of the 26 million people with congenital deafness globally.
However, several success stories announced last week are being seen as a turning point.
Photo: Children’s Hospital of Philadelphia via AP
On Tuesday last week, the Children’s Hospital of Philadelphia in Pennsylvania revealed that 11-year-old Aissam Dam, who was born deaf, was now “literally hearing sound for the first time in his life.”
Aissam still has mild-to-moderate hearing loss and might never learn to talk because the brain’s window for acquiring speech closes around the age of five.
However, a trial in China, the results of which were announced in The Lancet journal on Thursday, tested a similar treatment on six younger children.
Five gained the ability to hear, according to the findings of the trial that started in 2022, making it the first to have tested the gene therapy on humans.
Some of the children were already able to speak thanks to a cochlear implant — which they now no longer need, study coauthor Zheng-yi Chen of the Massachusetts Eye and Ear hospital said.
However, one, a baby only a year old, had never been able to communicate verbally, Chen said.
Chen said that after the treatment, when the mother asked the baby “Who am I?” the baby responded: “Mama.”
When asked what a chicken sounds like, the baby responded: “Coo-coo.”
“Everyone just cried with joy, it’s really amazing,” Chen said, adding that the baby was expected to grow up speaking normally.
Not since cochlear implants were invented 60 years has there been such an advance, Chen said, adding that the therapy “symbolizes a new era in the fight against all types of hearing loss.”
For now, the trials in China, the US and another announced in France this week all use a similar technique to focus on people born with a mutation of the OTOF gene.
This defect means they can no longer produce the protein otoferlin, which is needed for hair cells in the inner ear to convert sound vibrations into electrical signals that can be sent to the brain.
The treatment involves injecting a harmless virus into the inner ear that smuggles in a working version of the OTOF gene, restoring hearing.
The French trial is to focus on babies aged 12 months to 31 months, in the hopes it can “enable the acquisition of language”, said Nawal Ouzren, CEO of the firm Sensorion developing the treatment.
Natalie Loundon, a French doctor and hearing loss expert, called the technique “a game changer, a technological advance that will revolutionize therapeutic care.”
“The idea is to be able to offer this treatment to children rather than an implant, which is not always received well,” she said.
For the China-based trial, the researchers are to continue to study the participants to find out if their improved hearing lasts.
Chen estimated that the treatment tested in that trial could be ready to apply for regulatory approval within three to five years.
However, this particular treatment could only help a fraction of those born deaf.
About one in every 1,000 children are born deaf due to gene defects, but a lack of otoferlin is the cause of only about three percent of those cases.
More than 150 other genes have been discovered that trigger genetic hearing loss.
However, Chen had some good news.
So far, the otoferlin treatment seems to work just as well in humans as it did in during trials on mice — which is not always the case for such research.
Trials on mice targeting other gene defects that cause hearing loss have also been successful, Chen said.
Researchers therefore hope this first treatment opens the door to others.
Pasteur Institute in Paris, which pioneered the research on otoferlin, and Sensorion are already working on another therapy that focuses on a gene whose mutations are responsible for the most common forms of hereditary deafness.
North Korean leader Kim Jong-un sent Chinese President Xi Jinping (習近平) greetings with what appeared to be restrained rhetoric that comes as Pyongyang moves closer to Russia and depends less on its long-time Asian ally. Kim wished “the Chinese people greater success in building a modern socialist country,” in a reply message to Xi for his congratulations on North Korea’s birthday, the state-run Korean Central News Agency reported yesterday. The 190-word dispatch had little of the florid language that had been a staple of their correspondence, which has declined significantly this year, an analysis by Seoul-based specialist service NK Pro showed. It said
On an island of windswept tundra in the Bering Sea, hundreds of miles from mainland Alaska, a resident sitting outside their home saw — well, did they see it? They were pretty sure they saw it — a rat. The purported sighting would not have gotten attention in many places around the world, but it caused a stir on Saint Paul Island, which is part of the Pribilof Islands, a birding haven sometimes called the “Galapagos of the north” for its diversity of life. That is because rats that stow away on vessels can quickly populate and overrun remote islands, devastating bird
‘CLOSER TO THE END’: The Ukrainian leader said in an interview that only from a ‘strong position’ can Ukraine push Russian President Vladimir Putin ‘to stop the war’ Decisive actions by the US now could hasten the end of the Russian war against Ukraine next year, Ukrainian President Volodymyr Zelenskiy said on Monday after telling ABC News that his nation was “closer to the end of the war.” “Now, at the end of the year, we have a real opportunity to strengthen cooperation between Ukraine and the United States,” Zelenskiy said in a post on Telegram after meeting with a bipartisan delegation from the US Congress. “Decisive action now could hasten the just end of Russian aggression against Ukraine next year,” he wrote. Zelenskiy is in the US for the UN
A 64-year-old US woman took her own life inside a controversial suicide capsule at a Swiss woodland retreat, with Swiss police on Tuesday saying several people had been arrested. The space-age looking Sarco capsule, which fills with nitrogen and causes death by hypoxia, was used on Monday outside a village near the German border. The portable human-sized pod, self-operated by a button inside, has raised a host of legal and ethical questions in Switzerland. Active euthanasia is banned in the country, but assisted dying has been legal for decades. On the same day it was used, Swiss Department of Home